SVRA ▼ -1.8% - Savara Inc. $SVRA Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 12-OCT-2026 04:06 PM ET